Literature DB >> 11665828

Topiramate-induced metabolic acidosis: report of two cases.

C H Ko1, C K Kong.   

Abstract

Two children who presented with symptomatic metabolic acidosis after being put on topiramate (TPM) are reported. The first patient was an 11-year-old male with refractory complex partial epilepsy who was put on TPM for 13 months. He developed hyperventilation 1 week after increasing the dose to 300 mg/day. Arterial blood gas revealed hyperchloraemic metabolic acidosis with partial respiratory compensation: pH 7.36, PCO2 27.2 mmHg, bicarbonate 14.9 mEq/L, base excess -8.9 mmol/L. Hyperventilation and acidosis resolved after administration of sodium bicarbonate and reduction of the dose of TPM. The second patient was a female who developed increasing irritability at age 16 months and 21 months, each time associated with introduction of TPM and resolved promptly upon withdrawal of the drug. Venous blood gas taken during the second episode revealed pH 7.34, PCO2 37.4 mmHg, bicarbonate 20.4 mEq/L, base excess -4.2 mmol/L. The predominant mechanism of TPM-induced hyperventilation involves inhibition of carbonic anhydrase at the proximal renal tubule, resulting in impaired proximal bicarbonate reabsorption. The occurrence of hyperpnoea or mental status change in any patient who is on TPM should prompt an urgent blood gas sampling, with correction of the acid-base disturbances accordingly.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11665828     DOI: 10.1017/s0012162201001268

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  8 in total

Review 1.  Diabetes and epilepsy in children and adolescents.

Authors:  M Loredana Marcovecchio; Marianna Immacolata Petrosino; Francesco Chiarelli
Journal:  Curr Diab Rep       Date:  2015-04       Impact factor: 4.810

Review 2.  Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review.

Authors:  Valentina G Dell'Orto; Eva A Belotti; Barbara Goeggel-Simonetti; Giacomo D Simonetti; Gian Paolo Ramelli; Mario G Bianchetti; Sebastiano A G Lava
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

3.  Prevalence and spot urine risk factors for renal stones in children taking topiramate.

Authors:  Nicol Corbin Bush; Katherine Twombley; Justin Ahn; Carlos Oliveira; Susan Arnold; Naim M Maalouf; Khashayar Sakhaee
Journal:  J Pediatr Urol       Date:  2013-02-01       Impact factor: 1.830

Review 4.  Use of second-generation antiepileptic drugs in the pediatric population.

Authors:  Allison M Chung; Lea S Eiland
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 5.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 6.  Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review.

Authors:  Martin J Brodie; Frank Besag; Alan B Ettinger; Marco Mula; Gabriella Gobbi; Stefano Comai; Albert P Aldenkamp; Bernhard J Steinhoff
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

7.  The frequency and severity of metabolic acidosis related to topiramate.

Authors:  Hatice Türe; Özgül Keskin; Ülkem Çakır; Canan Aykut Bingöl; Uğur Türe
Journal:  J Int Med Res       Date:  2016-10-27       Impact factor: 1.671

8.  Mixed acid-base disorder secondary to topiramate use in traumatic brain injury.

Authors:  S Golla; U Anandh; A Balasubramaniam
Journal:  Indian J Nephrol       Date:  2016 Nov-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.